Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
30/07/202304:25GlobeNewswire Inc.Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRSNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/07/202319:45PR Newswire (US)REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/07/202319:45PR Newswire (US)INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)NASDAQ:REGNRegeneron Pharmaceuticals Inc
07/07/202319:45PR Newswire (US)REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/07/202306:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/07/202306:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/07/202319:45PR Newswire (US)INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/07/202304:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/07/202302:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/06/202306:01GlobeNewswire Inc.Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023NASDAQ:REGNRegeneron Pharmaceuticals Inc
28/06/202305:52Dow Jones NewsRegeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party FillerNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/06/202304:46GlobeNewswire Inc.Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular EdemaNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/06/202304:45GlobeNewswire Inc.FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party FillerNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/06/202306:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/06/202306:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/06/202306:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/06/202306:24Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:REGNRegeneron Pharmaceuticals Inc
26/05/202307:05GlobeNewswire Inc.Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/05/202307:00GlobeNewswire Inc.Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/05/202304:18GlobeNewswire Inc.Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/05/202305:32PR Newswire (US)High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023NASDAQ:REGNRegeneron Pharmaceuticals Inc
20/05/202302:54GlobeNewswire Inc.High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/05/202307:00Edgar (US Regulatory)Notice of Exempt Solicitation. Definitive Material. (px14a6g)NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/05/202306:01GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/05/202303:09Dow Jones NewsRegeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen -- UpdateNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/05/202302:59Dow Jones NewsRegeneron Says Supreme Court Ruling Ends Patent Dispute With AmgenNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/05/202301:45GlobeNewswire Inc.Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific InnovationNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202306:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202306:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/05/202321:14Dow Jones NewsRegeneron Posts Higher 1Q Sales, Boosted by Sanofi WorkNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN

Your Recent History

Delayed Upgrade Clock